Nasdaq: DFTX+6.09% 24h move
Price before$40.91Aug 11, 2026, 4:00 PM ET
First trade after$48.20Aug 12, 2026, 8:06 AM ET
24h later$43.40Aug 13, 2026, 7:59 AM ET
Complete Announced during: Premarket · announced Wed 8:05a ET (premarket); before = Tue close; first trade Wed 8:06a ET; time = SEC 8-K acceptance
Definium Therapeutics (Nasdaq: DFTX) reported topline results from a Phase 3 trial of DT120 in generalized anxiety disorder on August 12, 2026. The company said the trial met its primary endpoint.
Trial details
- Drug
- DT120
- Phase
- Phase 3
- Result
- Met endpointVoyage met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in HAM-A total score at Week 12.
- Safety
- We are deeply grateful to the patients, investigators, site personnel, and our team whose commitment made this milestone possible.” DT120 ODT was generally well tolerated, with treatment-emergent adverse events mild to moderate in severity, transient, and predominantly occurring on the day of…
- Sponsor
- Definium Therapeutics Nasdaq: DFTX
- Dates
- Announced Aug 12, 2026, 8:05 AM ET (SEC 8-K filing time)
About this trial
This Phase 3 trial tested DT120 in Generalized Anxiety Disorder. Definium Therapeutics reported that the trial met its primary endpoint.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.